Skip to main content
. 2003 Mar;47(3):1068–1071. doi: 10.1128/AAC.47.3.1068-1071.2003

TABLE 1.

In vitro susceptibilities of 3,959 clinical isolates of Candida spp. to caspofungin, fluconazole, and itraconazolea

Organism (no. tested) and antifungal agent MIC (μg/ml)b
% Susceptible at MIC (μg/ml) of:
Range 50% 90% 0.12 0.25 0.5 1 2 4 8
C. albicans (2,453)
    Caspofungin 0.007->8 0.12 0.25 79 97 99 99 99 99 99
    Fluconazole 0.12->128 0.25 0.5 24 82 91 94 95 96 97c
    Itraconazole 0.007->8 0.03 0.12 93d 96 98 99 99 99 99
C. glabrata (512)
    Caspofungin 0.007->8 0.12 0.25 58 91 99 99 99 99 99
    Fluconazole 0.12->128 8 32 0.2 0.6 1 2 12 33 60c
    Itraconazole 0.007->8 1 2 4d 18 46 80 91 94 96
C. parapsilosis (420)
    Caspofungin 0.03->8 1 4 2 6 25 60 87 95 99
    Fluconazole 0.12-64 0.5 2 1 11 51 78 93 97 99c
    Itraconazole 0.015-2 0.12 0.25 54d 90 99 99 100
C. tropicalis (285)
    Caspofungin 0.03->8 0.12 0.5 60 86 96 98 98 98 98
    Fluconazole 0.12->128 0.5 2 2 20 55 82 95 97 98c
    Itraconazole 0.015->8 0.12 0.5 58d 86 96 99 99 99 99
C. dubliniensis (88)
    Caspofungin 0.015-1 0.25 0.5 35 83 98 100
    Fluconazole 0.12->128 0.25 16 45 81 84 85 85 85 89c
    Itraconazole 0.015->8 0.06 0.25 84d 94 98 98 98 98 98
C. guilliermondii (75)
    Caspofungin 0.12->8 >8 >8 1 3 5 5 7 11 13
    Fluconazole 0.25->128 4 16 0 1 2 6 21 64 81c
    Itraconazole 0.03->8 1 1 7d 24 48 97 97 99 99
C. krusei (72)
    Caspofungin 0.12-2 1 1 1 10 43 99 100
    Fluconazole 4-128 32 64 0 0 0 0 0 1 5c
    Itraconazole 0.12-2 0.5 1 2d 18 57 95 100
C. lusitaniae (26)
    Caspofungin 0.12-2 0.5 1 11 23 81 96 100
    Fluconazole 0.12-16 0.5 2 2 38 64 86 97 97 98c
    Itraconazole 0.03-2 0.12 0.25 50d 91 98 98 100
C. famata (9)
    Caspofungin 0.06->8 4 11 11 22 33 44 56 56
    Fluconazole 0.25-16 2 0 13 33 47 53 73 89c
    Itraconazole 0.06-1 0.25 33d 60 80 100
Candida spp.e (19)
    Caspofungin 0.03-8 0.5 1 25 31 75 94 94 94 100
    Fluconazole 0.12-128 4 64 4 7 11 25 39 75 86c
    Itraconazole 0.015->8 0.25 1 29d 68 86 96 96 96 96
a

BMD testing according to NCCLS M27-A2 (17).

b

50% and 90%, MICs encompassing 50 and 90% of isolates tested, respectively.

c

Percentage of isolates susceptible to fluconazole at the NCCLS breakpoint of ≤8 μg/ml.

d

Percentage of isolates susceptible to itraconazole at the NCCLS breakpoint of ≤0.12 μg/ml.

e

Includes C. kefyr (four isolates), C. rugosa (six isolates), C. pelliculosa (three isolates), C. lambica (two isolates), and one isolate each of C. lipolytica, C. humicola, and C. zeylanoides.